SCHEMBL2439673

SCHEMBL2439673

N#Cc1c(O)nsc1Nc1ccc(Br)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.49
RECQL P46063 1/20 0.49
ALDH1A1 P00352 5/20 0.45
RAB9A P51151 2/20 0.45
LMNA P02545 2/20 0.45
POLB P06746 1/20 0.45
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MAPT P10636 4/20 0.41
EPAS1 Q99814 1/20 0.37
MAP2K1 Q02750 3/20 0.35
USP2 O75604 1/20 0.35
CDK4 P11802 1/20 0.34
CCND3 P30281 1/20 0.34
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5941017 0.98 HTT (0.48) HTTRECQLALDH1A1RAB9ALMNA
SCHEMBL2436480 0.93 MAPT (0.45) HTTRECQLALDH1A1RAB9ALMNA
SCHEMBL21917164 0.85 HTT (0.56) HTTRECQLALDH1A1RAB9ALMNA
SCHEMBL5941039 0.85 HTT (0.49) HTTRECQLALDH1A1RAB9ALMNA
SCHEMBL1228956 0.85 MAPT (0.50) HTTRECQLALDH1A1RAB9ALMNA
SCHEMBL5941099 0.85 HTT (0.64) HTTRECQLALDH1A1RAB9ALMNA
SCHEMBL2440881 0.85 HTT (0.49) HTTRECQLALDH1A1RAB9ALMNA
SCHEMBL3527060 0.84 HTT (0.68) HTTRECQLALDH1A1RAB9ALMNA
SCHEMBL5941015 0.83 MAP2K1 (0.54) HTTRECQLALDH1A1RAB9ALMNA
SCHEMBL13546620 0.82 HTT (0.50) HTTRECQLALDH1A1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989451-B2 Substituted isothiazole compounds are useful for treating the diseases associated with abnormality in protein kinases(especially MAP kinases) VALEANT RESEARCH & DEVELOPMENT (US) 2006-01-24 US claimed
EP-2362909-A2 MAMMALIAN GENES INVOLVED IN INFECTION Zirus, Inc. (US) 2011-09-07 EP disclosed
WO-2010039778-A2 MAMMALIAN GENES INVOLVED IN INFECTION Zirus, Inc. (US) 2010-04-08 WO disclosed
US-6989451-B2 Substituted isothiazole compounds are useful for treating the diseases associated with abnormality in protein kinases(especially MAP kinases) VALEANT RESEARCH & DEVELOPMENT (US) 2006-01-24 US disclosed
US-20040039037-A1 Heterocyclic compounds and uses thereof VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA (PL) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039037-A1 Heterocyclic compounds and uses thereof MAP3K1, MAP3K20, MAP4K2 HTT 2684/4885RECQL 3054/4885ALDH1A1 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.